Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Sales (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Return on Sales readings, the most recent being 1.18% for Q4 2025.

  • On a quarterly basis, Return on Sales fell 93.0% to 1.18% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.11%, a 10.0% increase, with the full-year FY2025 number at 0.11%, up 25.0% from a year prior.
  • Return on Sales hit 1.18% in Q4 2025 for Aligos Therapeutics, down from 0.43% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 1.39% in Q1 2025 to a low of 1.64% in Q1 2023.
  • Median Return on Sales over the past 5 years was 0.2% (2021), compared with a mean of 0.29%.
  • Biggest five-year swings in Return on Sales: plummeted -150bps in 2023 and later soared 189bps in 2025.
  • Aligos Therapeutics' Return on Sales stood at 1.03% in 2021, then soared by 98bps to 0.02% in 2022, then plummeted by -782bps to 0.14% in 2023, then plummeted by -79bps to 0.25% in 2024, then plummeted by -373bps to 1.18% in 2025.
  • The last three reported values for Return on Sales were 1.18% (Q4 2025), 0.43% (Q3 2025), and 0.16% (Q2 2025) per Business Quant data.